Solventum Corporation (SOLV) Stock Forecast & Price Target

Solventum is expected to experience steady growth in the near future with its focus on expanding through both organic and inorganic means, while also considering divestiture in non-core areas. Its recent shift to "offensive M&A" and focus on tuck-in acquisitions, combined with its strong financial outlook for the next few years, suggest that the company is well positioned for long-term success. The company's recent spin-off from 3M has allowed it to focus on its core healthcare segments and unlock value for shareholders.

Solventum is facing potential risks such as decreases in global healthcare spending and competitive pressure that could impede its stock from achieving its price target. These risks are further exacerbated by potential delays in separation and new FDA regulatory actions, as well as potential higher costs associated with TSA agreements and decreased growth in key markets. Despite the initiation of a share repurchase program, with ~$1bn authorized, there is also the risk of increased competition and insider selling. Overall, these risks outweigh any potential price gains for Solventum's stock.